Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (Nasdaq: AXSM) is a fully integrated biopharmaceutical company developing and commercializing medicines for central nervous system conditions. Its three U.S.-approved commercial products are AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness associated with… From the company’s description.
In fiscal 2025, Axsome Therapeutics, Inc. reported revenue of $638.50M, up 65.5% from fiscal 2024, and a net loss of $183.17M. Its operating margin was −26.1%, and operations used $93.41M in cash. Over the twelve months to Jun 30, 2026, revenue was $776.57M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Axsome Therapeutics, Inc. does
In the company’s own words
Axsome Therapeutics, Inc. (Nasdaq: AXSM) is a fully integrated biopharmaceutical company developing and commercializing medicines for central nervous system conditions. Its three U.S.-approved commercial products are AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute treatment of migraine in adults. The company’s pipeline includes candidates for Alzheimer’s disease agitation, smoking cessation, ADHD, depression with excessive daytime sleepiness, binge eating disorder, shift work disorder, narcolepsy, fibromyalgia and epilepsy. Axsome develops products using proprietary medicinal chemistry and formulation technologies and has a U.S. commercial infrastructure, while partnering for some international commercialization. It acquired U.S. and ex-U.S. rights to SUNOSI from Jazz Pharmaceuticals in 2022 and launched SYMBRAVO in 2025. Revenue from its three commercial products totaled $638.5 million in fiscal 2025. Its website is https://www.axsome.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1579428
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Axsome Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Axsome Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Axsome Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Axsome Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Axsome Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Axsome Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”